Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12617767-B2

Patent

Publication Date

2026-05-05

Expiration Date


Abstract

Described herein are pharmaceutically acceptable salts of a somatostatin modulator, crystalline forms of the pharmaceutically acceptable salts of the somatostatin modulator, methods of making such salts and crystalline forms, pharmaceutical compositions and medicaments comprising such salts and crystalline forms, and methods of using such salts and crystalline forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Core Innovation

The invention covers a mesylate salt of 3-(4-(4-aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl)-2-hydroxybenzonitrile, or a solvate thereof, in amorphous and crystalline forms. Solid-state characterization distinguishes these forms through thermal-analysis profiles, including Differential Scanning Calorimetry, Thermogravimetric Analysis, and Dynamic Vapor Sorption, as well as X-ray powder diffraction patterns. Crystalline forms include hydrates, solvent solvates, and additional crystalline forms displaying distinct stability and interconversion behaviors.

The disclosure describes the preparation of the dimesylate salt, pharmaceutical compositions, and proposed SSTR2-modulating therapeutic uses. Documented treatment contexts include acromegaly, neuroendocrine tumors, cancer, pain, and inflammatory, ophthalmic, neurologic, and respiratory conditions. Because background and summary sections are omitted from the supplied patent content, the specific technical problem being solved is not explicitly described in patent.

Claims Coverage

The supplied claims identify one independent claim directed to the mesylate salt or a solvate thereof across four inventive features.

Amorphous dimesylate form

An amorphous form of the specified dimesylate characterized by a modulated Differential Scanning Calorimetry thermogram, a glass transition temperature, a Thermogravimetric Analysis pattern, or a combination thereof.

Crystalline hydrate forms

Crystalline hydrate forms of the specified dimesylate characterized by specified X-ray powder diffraction pattern reflections.

Crystalline solvent solvates

Crystalline isopropyl, tetrahydrofuran, methyl isobutyl ketone, ethyl acetate, isopropyl acetate, acetone, and acetonitrile solvates of the specified dimesylate, each characterized by specified X-ray powder diffraction pattern reflections.

Crystalline dimesylate forms

Crystalline forms of the specified dimesylate characterized by specified X-ray powder diffraction pattern reflections.

The independent claim covers the specified mesylate salt or a solvate thereof across amorphous, crystalline hydrate, crystalline solvate, and other crystalline forms, distinguished by X-ray powder diffraction patterns and thermal-analysis characteristics.

Stated Advantages

Recrystallization and metal-scavenger treatments reduce residual palladium, with one reported example exhibiting no detectable palladium.

Documented Applications

A pharmaceutical composition comprising the mesylate salt or a solvate thereof and at least one pharmaceutically acceptable excipient.

Treatment of a mammal with acromegaly, a neuroendocrine tumor, an ophthalmic disease or condition, neuropathy, nephropathy, a respiratory disease or condition, cancer, pain, a neurodegenerative disease or condition, an inflammatory disease or condition, or a psychiatric disease or condition.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.